Incomplete Expansion of Palmaz-Schatz Stents despite High-Pressure Implantation Technique: Impact on Target Lesion Revascularization

Erwin Blessing  Dirk Hausmann  Matthias Sturm  Hans-Georg Wolpers  Ivo Amende  Andreas Mügge
Division of Cardiology, Department of Internal Medicine, Hannover Medical School, Germany

Key Words
High-pressure implantation • Stent expansion • Intravascular ultrasound • Restenosis

Abstract
Improved expansion of stents using high-pressure implantation technique with subsequent antiplatelet therapy has improved patient outcome regarding the incidence of subacute stent thrombosis, bleeding complications and restenosis. Whether high-pressure implantation per se guarantees adequate stent expansion remains unclear. The aim of the study was to determine (1) stent expansion after high-pressure implantation technique and (2) whether stent expansion influences rate of target lesion revascularization within 6 months of follow-up. One hundred Palmaz-Schatz stents were implanted in 98 lesions (91 native vessels, 7 graft vessels) of 94 patients using high-pressure implantation technique (balloon pressure 12–20 atm). Stent expansion was investigated using intravascular ultrasound imaging (IVUS). Clinical follow-up of the patients was performed for 6 months. After implantation, stent/mean reference ratio was 0.81 ± 0.16. Noncompliant balloons used for implantation were chosen by angiographic criteria. Mean balloon/reference ratio was 1.08 ± 0.22; therefore balloons were not undersized. Additional balloon dilatation using higher pressures and/or larger balloons based on IVUS criteria and subsequent IVUS measurements was performed in 52 patients (55%); in these patients, stent expansion improved from 79 ± 16 to 91 ± 15% (mean ± SD) of average reference areas (p < 0.002). Within the 6 months’ clinical follow-up, target lesion revascularization was performed in 19 patients (20%). The only prognostic factors for the development of in-stent restenosis requiring target lesion revascularization were the vessel size (p < 0.05) and the extent of plaque distal to the stents (p < 0.05). Implantation of Palmaz-Schatz stents using high-pressure technique does not guarantee adequate stent expansion. Additional dilation with higher pressures and/or larger balloons improves stent expansion. The size of the stented vessel and the extent of plaque at the distal stent end (residual outflow stenosis) but not the degree of stent expansion were predictors for target lesion revascularization within 6 months’ follow-up.

Introduction
Prior studies using intravascular ultrasound imaging (IVUS) demonstrated the absence of adequate stent expansion despite an acceptable angiographic result in
>80% of patients before the era of high-pressure implantation [1, 2]. In these days, stent thrombosis occurred in 3–4% of patients undergoing elective stent placement [3–5]. Consequent anticoagulation with heparin, coumadin and platelet inhibitors was therefore necessary. Anticoagulation, on the other hand, can lead to severe bleeding complications and also significantly prolongs the hospital stay. This has prompted investigators to develop a more aggressive strategy based on high-pressure balloon dilatation. Colombo and coworkers [6] showed that anticoagulation therapy was not obligatory as long as adequate stent expansion was achieved using high-pressure implantation technique, supporting the concept that stent thrombosis might be due to incomplete stent dilatation rather than to the thrombogenicity of the metallic struts.

Whether the incidence of acute complications as well as the restenosis rate after implantation of intracoronary stents can be further decreased using IVUS guidance is investigated in ongoing trials [7, 8]. The goal of this study was to determine (1) whether high-pressure implantation technique per se guarantees adequate stent expansion, and (2) whether stent expansion influences rate of target lesion revascularization at a 6-month follow-up.

**Methods**

**Patients**

Between October 1994 and July 1996 94 consecutive patients (80 male, 14 female; mean age 61 ± 10 years) underwent IVUS-guided implantation of 100 Palmaz-Schatz stents (Johnson & Johnson) in 98 coronary lesions (79 de novo lesions, 19 restenotic lesions). Indication for catheterization were stable angina pectoris (n = 59), unstable angina pectoris (n = 15) or prior myocardial infarction (n = 20). All patients were treated and imaged only after having given written, informed consent for participation in this study.

**Stent Implantation**

Preprocedural angiographic stenosis was ≥75% by visual estimate in all patients. The 98 lesions were located in the left anterior descending artery (n = 54), right coronary artery (n = 23), saphenous vein grafts (n = 7). The types of Palmaz-Schatz stent implanted were: PS 104 (n = 23), PS 153 (n = 35), PS 154A (n = 30), PS 153 (n = 7) and PS 204C (n = 5). Noncompliant balloon catheters used for stent implantation were chosen by angiographic criteria with a mean diameter of 3.3 ± 0.4 mm (2.5–5.0 mm). Inflation pressures for the initial stent deployment ranged between 12 and 20 atm (15.3 ± 3.9 atm). Patients were treated with a bolus dose of 10,000 U of heparin at the time of the sheath insertion and a repeat bolus dose of 5,000 U of heparin before stent implantation. After implantation, a combination of heparin and oral anticoagulant (n = 27) or antiplatelet (ticlopidine and/or aspirin) therapy (n = 68) was administered. In case of coumadin therapy, target range of international normalized ratio was set between 2.0 and 3.0 for 3 months. Ticlopidine therapy was discontinued after 4 weeks.

**Results**

**Stent Implantation**

IVUS imaging could be performed in all patients without complications. In 8 patients with ostial lesions, the proximal reference lumen area could not be determined. In these cases, only the distal reference was used to determine stent expansion. Mean lumen areas were 8.94 ± 2.92 mm² for the proximal and 8.26 ± 2.81 mm² for the distal reference section (mean ± SD). Area of minimal lumen within the stents was 6.90 ± 3.22 mm². Therefore average of all stent expansions was calculated as 81 ± 15%. Figure 1 shows the relation between minimal lumen area within the stents and the mean reference area; 89% of...
the stents were smaller than the mean reference lumen areas. Balloon catheters used for stent implantation had a nominal area of $8.88 \pm 2.40 \text{ mm}^2$. The quotient of the nominal areas of the balloons used for stent deployment and the mean reference area was 1.07 on average, standard deviation was $\pm 0.23$ ($y = 0.70x + 2.8$). Therefore, balloon catheters chosen by angiographic criteria were not undersized compared with the reference segments (fig. 2). Comparison between nominal balloon areas and minimal stent lumen areas revealed a mean ratio of $1.33 \pm 0.21$ ($y = 0.91x + 2.6$). In almost all patients, balloons used for the interventions were larger than the minimal lumen within the stents (fig. 3).

As shown in table 1, the degree of stent expansion did not differ significantly between the left anterior descending artery, the circumflex artery, right coronary artery and bypass grafts. Stent expansion was also comparable regarding the etiology of the stenosis (de novo stenosis, re-stenosis) and the different indications for stenting (primary, bail-out). Finally, there was no statistical difference for stent expansion regarding the different stent sizes.

In 71 of the 94 patients (76%), stent expansion by IVUS was considered as not optimal. In these patients, additional balloon dilatation was performed using larger...
Table 1. Lesion characteristics and stent expansion

| Vessel | n | %    |
|--------|---|------|
| LAD    | 54| 79±15| n.s. |
| RCA    | 23| 80±11|
| LCx    | 14| 82±21|
| CABG   | 7 | 87±28|
| Stenosis |  |      |
| de novo | 79| 79±15| n.s. |
| restenosis | 19| 86±16|      |
| Stent |  |      |
| primary | 50| 79±15| n.s. |
| bail-out | 50| 82±16|      |
| <3.5 mm | 57| 78±15| n.s. |
| >3.5 mm | 43| 85±15|      |

Average stent expansion in the listed subgroups of the different treated vessels, lesion characteristics, indications for stenting and size of stented vessels are shown. No statistical significant difference in stent expansion was found between the vessels, the etiology of the lesions, the indications for stenting and the size of stented vessel.

LAD = Left anterior descending artery; RCA = right coronary artery; LCx = Circumflex artery; CABG = coronary artery bypass graft; n.s. = nonsignificant.

balloons (3.48 ± 0.48 mm, range 2.5–5.0 mm) and/or higher dilatation pressure (17.7 ± 2.6 atm, range 14–20 atm). In 52 of these 71 patients (73%), the final result was assessed with IVUS imaging. In this cohort of patients, stent expansion improved from 79 ± 16 to 91 ± 15% (p < 0.002; fig. 4). Residual stenosis of the angiographic silent plaque was calculated as 43.1 ± 12.5% for the inflow stenosis and 37.4 ± 14.7% for the outflow stenosis.

Follow-Up

27 patients have been anticoagulated with coumadin. 66 patients were treated with ticlopidine and aspirin, 2 received only aspirin. 2 patients had severe complications during their hospital stay; one patient had a subacute stent thrombosis resulting in an acute myocardial infarction, another patient underwent bypass surgery after a subacute stent thrombosis. Both patients were anticoagulated with coumadin. International normalized ratio was within the therapeutic range (2.0–3.0). Minimal stent lumen diameter was 4.85 mm in one and 3.89 mm in the other patient. Stent expansion was 92 and 98%, respectively. Thrombus formation, however, was already visible by IVUS at the time of the intervention and diminished after additional dilatation was performed. 8 patients underwent groin surgery, and 2 required blood transfusions after severe bleeding complications.

Patients were followed up for 6 months with exercise tests and nuclear imaging if indicated; 8 patients (9%) were lost for follow-up as they did not appear in our outpatient clinic and could not be reached by phone or mail. 19 of the remaining 86 patients (22%) required target lesion revascularization within the 6-month period. In 6 patients in-stent conventional balloon angioplasty was performed, 7 patients underwent placement of another stent in the target vessel. In 4 patients conventional coronary bypass grafting was performed, in 2 patients revascularization was achieved using the minimal invasive approach. 1 patient presented with positive thallium stress testing but refused to undergo control angiography. All the other patients were clinically stable, showed no positive stress test and no significant restenosis of the stented vessel on control angiography, if performed.
Table 2. Target lesion revascularization

|                         | Group A          | Group B          | p   |
|-------------------------|------------------|------------------|-----|
| Stable/unstable/post-inf. angina | 38/10/19      | 16/3/0          | n.s.|
| LAD/LCx/RCA/CABG        | 36/10/18/3      | 13/3/2/1        | n.s.|
| Balloon size, mm        | 3.6 ± 0.5        | 3.0 ± 0.2       | p < 0.001|
| Maximal pressure, atm   | 15.2 ± 3.9       | 15.9 ± 3.9      | n.s.|
| Stent expansion, %      | 90 ± 15          | 82 ± 13         | n.s.|
| Minimal stent lumen, mm²| 7.5 ± 2.5        | 6.0 ± 1.8       | p < 0.05|
| Inflow plaque stenosis, %| 42 ± 12         | 46 ± 14         | n.s.|
| Outflow plaque stenosis, %| 35 ± 16         | 42 ± 11         | p < 0.05|

Statistical significant difference between patient with (group B) and without (group A) target lesion revascularization was found for minimal stent lumen, balloon size and degree of outflow plaque stenosis. Post-inf. angina = Postmyocardial infarction angina; LAD = left anterior descending artery; LCx = circumflex artery; RCA = right coronary artery; CABG = coronary artery bypass graft; n.s. = nonsignificant.

and without revascularization (p < 0.05). The degree of stent expansion at the time of primary implantation was not different (p = nonsignificant). The amount of plaque located at the distal end of the stents was significantly different in patients with and without target lesion revascularization (p < 0.05).

Discussion

There are established criteria for optimal stent expansion assessed by intravascular ultrasound [6]. A first criterion is a qualitative evaluation of the stent site involving the achievement of good stent apposition to the vessel wall. Second, minimal stent lumen area should be equal or greater than the reference lumen area (stent expansion ≥ 100%). Third, no significant residual stenosis (> 60%) should be proximal or distal to the stent [6]. Previous studies showed that an incomplete apposition of the stent struts, a residual lumen narrowing or an irregular eccentric lumen in the stented segment was still present in up to 88% of the cases when the angiographic result was considered optimal by an experienced operator [2, 6]. This has prompted investigators to develop a more aggressive strategy based on high-pressure balloon dilatation [1, 2, 6, 10].

The question of whether high-pressure implantation technique per se guarantees adequate expansion of Palmaz-Schatz stents was addressed previously. Goerge et al. [11] compared two groups of patients undergoing either conventional implantation of Palmaz-Schatz stents (patients treated between 1991 and 1992) or using the high-pressure approach (between 1993 and 1994). Average minimal lumen diameter measured by IVUS increased from 2.55 ± 0.41 to 3.14 ± 0.37 mm in the group of patients undergoing high-pressure implantation. However, despite the use of high-pressure technique, not all patients had homogenous stent geometry or optimal stent expansion. In 9 out of the 24 patients, stent apposition was considered not optimal. Stone and coworkers [12] performed serial IVUS investigations after sequential balloon inflation of Palmaz-Schatz stents at 12, 15 and 18 atm using noncompliant balloons with a mean balloon to artery ratio of 1.13 ± 0.16. Minimal lumen area within the stents increased progressively from 7.7 ± 2.1 to 9.2 ± 2.4 mm² due to an increase of implantation pressure. Commonly used criteria for optimal stent expansion, however, were only met by 81% of the patients, even after applying 18 atm. In another study, Botas et al. [13] performed IVUS evaluations of stent expansion of different stent types. Stents were implanted with slightly oversized catheters (balloon/artery ratio of 1.15 ± 0.18) using 14.5 ± 2 atm. Mean stent expansion was calculated as 82 ± 20%, only 29% of the stents showed an expansion of over 90%. Interestingly, stent expansion did not vary among different stent types.

In our study, 89% of the stents were smaller than the mean reference lumen areas; mean stent expansion was 81 ± 15%. Results of stent implantation was considered as not optimal by IVUS criteria in 76% of the patients. Additional balloon dilatations improved stent expansion significantly. The ratio of the nominal balloon areas used for stent implantation and the mean reference area was 1.07 ± 0.23, indicating that the balloon catheters chosen by angiographic criteria were not undersized compared with the reference segments. Comparison between nominal balloon areas and minimal stent lumen areas revealed a ratio of 1.33 ± 0.21. Therefore, almost all balloons used

106 Cardiology 1999;91:102–108
for the interventions were larger than the minimal lumen within the stents.

Regarding the mechanisms of residual lumen stenosis after high-pressure stent implantation, quantitative coronary angiography and IVUS studies were performed. They support the hypothesis that balloon underexpansion as well as elastic recoil are responsible for residual lumen stenosis, suggesting that plaque characteristics and stent radial strength deserve further investigations [14].

Optimal ultrasound-guided stent expansion was initially targeted to the prevention of subacute thrombosis, but this strategy can also have an impact on the reduction of restenosis. Preliminary studies have shown that IVUS-guided stent placement may result in a lower restenosis rate as compared to the angiographic-guided approach [7, 8, 15–17]. Data from the CRUISE trial, the IVUS substudy of the STARS trial suggest that ultrasound guidance results not only in a significantly larger minimal stent lumen, but also in a 39% relative reduction in target vessel revascularization (8.9 vs. 14.8%) [18].

As shown in previous studies, development of in-stent restenosis depends on several factors, including the size of the stented vessel [3, 4, 19–21]. In our study, vessel size also proved to be a prognostic factor regarding the incidence of target lesion revascularization. Minimal stent lumen in the group of patients requiring target lesion revascularization was 6.0 ± 1.8 compared with 7.5 ± 2.5 mm² in those without a revascularization procedure (p < 0.05). However, expansion of the stents did not differ significantly in both groups of patients. Residual plaque stenosis proximal to the stents (inflow) was 45 ± 14% in patients with and 42 ± 12% in patients without target lesion revascularization (nonsignificant). Most interestingly, data for the residual plaque stenosis distal to the stents (outflow) were 43 ± 10 and 35 ± 15%, respectively (p < 0.05). These data suggest that focusing on the minimal stent lumen and avoidance of residual outflow stenosis seems to be a more appropriate strategy than focusing on the mere stent expansion. Of course, the aggressive use of larger balloons and higher pressure must be tempered with the risk of vessel rupture and increased intimal response due to vessel injury [22–27].

Limitations of the Study

Considering the issue of stent thrombosis, it should be mentioned that the quoted studies employed antiplatelet therapy in addition to high-pressure technique. Several recent studies showed significant reductions in stent thrombosis solely by employment of antiplatelet therapy and elimination of anticoagulation with coumadin [28–30]. However, adequacy of stent deployment remains an important issue regarding the rate of target lesion revascularization. One limitation of the present study is that nominal balloon diameters (diameter of the balloon catheters provided by the manufacturers depending on inflation pressure) were used to assess balloon/reference and balloon/stent ratio. No QCA measurements were performed to determine actual balloon diameters. Due to radial forces provided by the plaque, the vessel wall and the stents themselves, balloon diameters might be overestimated. In the 8 patients with ostial lesions, proximal reference could not be determined. Therefore, only the distal reference area was used to calculate stent expansion which could lead to overestimation of stent expansion in those patients. Furthermore, final IVUS was performed only in 53 out of the 72 patients, who underwent additional dilatation after initial IVUS imaging. Angiographic follow-up data at 6 months was available in only 73 patients (78%); again, QCA was not performed for quantitative analysis. Target lesion revascularization depends on several factors and cannot be used to exactly assess the rate of in-stent restenosis. 8 patients were lost for clinical follow-up, possibly due to a better clinical outcome than those who underwent regular follow-up visits or control angiography which might increase the relative rate of target lesion revascularization in the followed-up patients. In 28 of the 86 patients, final IVUS was not performed after additional balloon dilatation; therefore actual stent expansion by IVUS after completion of the procedure was only known in 58 patients (67.4%). Furthermore, new stent designs, providing flexibility without an articulation site may already help to overcome the problem of plaque prolapse into the lumen contributing to in-stent restenosis, as observed in the first generation of Palmaz-Schatz stents.

Conclusions

Implantation of Palmaz-Schatz stents using high-pressure implantation technique and angiographic criteria does not guarantee ‘adequate’ stent expansion, as defined by IVUS criteria. Additional dilatation with higher pressure and/or larger balloons improves stent expansion significantly. The size of the stented vessel and the outflow plaque stenosis, but not the degree of stent expansion had an influence on the rate of target lesion revascularization within 6 months’ follow-up. These data suggest that minimal stent lumen and residual plaque stenosis seem to be more predictive parameters than mere stent expansion regarding the rate of target lesion revascularization.
Goerge G, Haude M, Ge J, Voegelie E, Gerber T, Rupprecht HJ, Meyer J, Erbel R: Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. J Am Coll Cardiol 1995;26:725–730.

Stone GW, Linneker M, St Gooaf F, Hodgson J, Overdaile J, Yock P, Fitzgerald P: Defining the relationship between stent implantation pressure and optimal expansion – Core lab analysis from the OSTI trial (abstract). Circulation 1996;94(suppl I):I-259.

Bots J, Elizaga J, Garcia E, Bermejo J, Soriano J, Abeyta M, Osende J, Fernandez A, Delcan JL: Intravascular ultrasound evaluation of stent implantation using high balloon pressures (abstract). Eur Heart J 1996;17:1020.

Bermejo J, Bots J, Garcia EJ, Elizaga J, Soria-no J, Abeyta M, Sarnago F, Delcan JL: Mechanism of residual lumen stenosis after high pressure stent implantation: A QCA and IVUS study (abstract). Circulation 1996;94(suppl I):I-199.

Blasini R, Zitzemann E, Schalkhauser F, Palon-cy R, Boekenhamp J, Walter H, Hadamitzki M, Neumann FJ, Richardt G, Schmitt C, Alt E, Schoenig A: Bedeutung einer IVUS-gesteuerten Optimierung koronarer Palmaz-Schatz Stent Implantation auf den klinischen und angiographischen Langzeitverlauf (abstract). Z Kardiovask Med 1996;15:137–140.

Albiero R, Rau T, Schlueter M, DiMarico C, Reimers B, Mathey DG, Schofer J, colorno A: Comparison of immediate and intermediate-term results of intravascular ultrasound versus angiography-guided Palmaz-Schatz stent implantation in matched lesions. Circulation 1997;96:2997–3005.

Stone GW, Hodgson JM, St Gooaf F, Frey A, Mudra H: Improved procedural result of coronary angioplasty with ultrasound guided balloon sizing: The CLOT pilot trial. Circulation 1997;95:2044–2052.

Filipps P, Roberger H, Nosaka H, Hamasaki N, Yokoi H, Kim K: Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observations in 20 patients. J Am Coll Cardiol 1991;17:433–439.

Schwarz R, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR: Restenosis after balloon angioplasty: A practical proliferation model in porcine coronary arteries. Circulation 1990;82:2190–2200.

de Jaegere P, Serruys PW, Bertrand M, Wie-gand V, Marquis JF, Vrolix M, Plessens J, Valeix B, Kober G, Bonnier H: Angiographic predictors of recurrence of restenosis after Wiktor stent implantation in native coronary arteries. Am J Cardiol 1993;72:165–170.

Savage MP, Fischman DL, Douglas JS, Pepine CJ, Werner JA, Bailey SR, Rake R, Goldberg S, for the SAVED Investigators: The dark side of high pressure stent deployment (abstract). J Am Coll Cardiol 1997:29(suppl A):368A.

Fernandez-Aviles F, Alonso JH, Duran JM, Gimero F, Garcia-Moran E, Paniagua J, Gari-cmartin I, Munoz JC: High-pressure increases late loss after coronary stenting (abstract). J Am Coll Cardiol 1997:29(suppl A):369A.

Schomig A, Neumann FJ, Kastrafti A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitza-nmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet therapy and with replacement of coronary-artery stents. N Engl J Med 1996;334:1084–1089.

Morice MC, Zemour G, Benveniste E, Biron Y, Bourdannec C, Paire G, Fajadet J, Gaspard P, Glatt B, Regnier P: Intracoronary stenting without replacement of the lesion. One month results of a French multicenter study. Cathet Cardiovasc Diagn 1995;35:1–7.

Karrillon GJ, Morice MC, Benveniste E, Bu-nof R, Aubry P, Cattan S, Chevalier B, Comme-mac P, Cribier A, Eiferman C, Grollier G, Guerin Y, Henry M, Lechef T, Livarek B, Louvard Y, Marco J, Makowski S, Monassier JP, Pernes JM, Ricou P, Spaulding C, Zemour G: Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antipatelet therapy, 30-day clinical outcome of the French Multicenter Registry. Circulation 1996;94:1519–1527.

References

1. Goldberg SL, Colombo A, Nakamura S, Alma-gor M, Maiello L, Tobis JM: Benefit of in-tra coronary ultrasound in the deployment of Pal-maz-Schatz stents. J Am Coll Cardiol 1994;24: 996–1003.

2. Nakamura S, Colombo A, Gaglione S, Almagor Y, Goldberg SL, Maiello L, Finci L, Tobis JM: Intracoronary ultrasound observations during stent implantation. Circulation 1994;89:2026–2034.

3. Serruys PW, de Jaegere P, Stemme F, Macaya C, Rutsch W, Sunamura M, Figulla H, Almagor Y, Mudra H, Macaya C, Zahn R, Grip L, Di Mar-coated Palmaz-Schatz stents in human coro-nary arteries. Circulation 1991;83:148–161.

4. Fischman DL, Leon MB, Baim D, Schatz RA, Penn I, Detre K, Savage MP, Veltri L, Ricci D, Nobuyoshi M, Clemen M, Heuser R, Almagor Y, Mudra H, Sunamura M, Figulla H, Almagor Y, Serruys PW, de Jaegere P, Kiemeneij F, Ma-

5. Schatz RA, Baim DS, Leon M, Ellis SG, Gol-denberg S, Hisfeld J, Clemen HS, Wbild C: Clinical experience with the Palmaz-Schatz coronary stent: Initial results of a multi-center study. Circulation 1991;83:148–161.

6. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg S, Tobis J: Intra coronary stenting without anti-coagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91: 1676–1688.

7. Mudra H, Sunamura M, Figulla H, Almagor Y, Maiello L, Martini G, Bilodeau L, Penn I, Colombo A, Hamm C, Bartorelli A, Rothman M, Nabilyou M, Yamaguchi T, Voudris V, Makovski S, Hausmann C, de Jaegere P: Six month clinical and angiographic outcome after IVUS guided stent implantation (abstract). J Am Coll Cardiol 1997:29:171A.

8. Mudra H, Macaya C, Zahn R, Grip L, Al-Mar-co, C, Rutsch W, Voudris V, Schachinger V, Henneke K-H: Interim analysis of the ‘Optimi- zation with ICUS to Reduce Stent Restenosis’ OPTICUS trial (abstract). Circulation 1998; 98(suppl II).

9. Blessing E, Hausmann D, Sturm M, Wolpers HG, Amende I, Mügge A: Intravascular ultra- sound guidance of stent implantation: Intraob-server and interobserver variability. Am Heart J 1999;137:368–371.

10. Serruys PW, Emanuelsson H, van der Giessen W, Lunn A, Kiemenej F, Macaya C, Rutsch W, Heyndrickx G, Suryapranata H, Legrand V, Goy JH, Matepne P, Bonnier H, Morice MC, Fajadet J, Belardi J, Colombo A, Garcia E, Ruygrok P, de Jaegere P, Morel MA: Heparin-coated Palmaz-Schatz stents in human coro-nary arteries. Early outcome of the Benestent-II pilot study. Circulation 1996;93:412–422.

Blessing/Hausmann/Sturm/Wolpers/ Amende/Mügge